Waste Management: It's Not Too Late To Buy This

Waste Management (WM) reported robust Q2 2025 results, with record revenues of $6.43 billion, up 19.03% year-over-year, and free cash flow surging 66.94% to a multi-year high of $813 million. The company provided an optimistic full-year 2025 outlook, raising FCF guidance to $2.8-$2.9 billion and reiterating adjusted operating EBITDA guidance, both indicating significant acceleration in growth from 2024 levels. Despite modest capital returns, the article initiates a 'buy' rating, citing strong fundamentals and potential for further EV/EBITDA multiple expansion.

Analysis

Waste Management, Inc. reported a robust second quarter for 2025, characterized by accelerating top-line growth and surging cash flows. Total revenues reached a record $6.43 billion, a 19.03% year-over-year increase, driven by strong organic growth in its core Collection and Disposal business and emerging traction in its new Healthcare Solutions segment. Profitability remained strong, with adjusted operating EBITDA growing 18.85% to $1.923 billion. While the consolidated EBITDA margin saw a minor contraction, this was attributed entirely to the lower-margin profile of the new healthcare segment; the core Legacy Business actually expanded its margin by 1.3 percentage points, indicating strong underlying operational efficiency. The most significant development was the 66.94% surge in free cash flow to a multi-year high of $813 million, aided by lower capital expenditures. This strength is projected to continue, as the company raised its full-year 2025 FCF guidance to a range implying 32.01% growth, a material acceleration from 2024. Despite this cash generation, capital returns to shareholders were modest, with a low dividend yield of 1.44% and minimal Q2 share repurchases, suggesting a strategic retention of cash for potential reinvestment. The company's forward EV/EBITDA multiple is elevated, but the outlook for accelerated EBITDA growth of 15.04% for the full year provides a fundamental basis for potential further expansion.

Key Decisions for Investors

• Given the accelerating growth in revenue, EBITDA, and free cash flow, investors may view the stock as a core holding, as the strong fundamentals and positive full-year guidance support the potential for continued valuation expansion.
• Investors should closely monitor management's capital allocation strategy, as the significant increase in free cash flow is not currently being directed towards substantial buybacks or dividend increases, implying a focus on internal reinvestment or future M&A.
• The primary metrics to watch are the margin development within the new Healthcare Solutions segment and the sustainability of FCF growth, especially considering the benefit from the one-time tax policy change.